Polip Hidung

01Pathophysiology

Nasal polyps arise from chronic type 2 inflammation of the sinonasal mucosa. The dominant immune pathway involves Th2 lymphocytes releasing IL-4, IL-5, and IL-13. IL-5 is the principal driver of eosinophil recruitment and survival within the tissue. These eosinophils degranulate and release toxic mediators (major basic protein, eosinophil cationic protein), which perpetuate mucosal damage, edema, and remodeling. Over time, the edematous mucosa herniates outward from the ostiomeatal complex, forming the characteristic pedunculated polyps.

This is why the patient develops progressive nasal obstruction: the polyps physically block airflow. Anosmia occurs because the polyps obstruct the olfactory cleft, preventing odorant molecules from reaching the olfactory epithelium in the cribriform plate region. The rhinorrhea and postnasal drip result from excessive mucus production driven by goblet cell hyperplasia, another consequence of IL-13 stimulation.

A critical association to understand is Samter triad (also called aspirin-exacerbated respiratory disease, or AERD). This triad consists of nasal polyps + asthma + aspirin/NSAID sensitivity. The mechanism involves a shift in arachidonic acid metabolism: cyclooxygenase (COX) is constitutively underexpressed, leading to decreased prostaglandin E2 (a bronchoprotective mediator), while the 5-lipoxygenase pathway is upregulated, producing excessive cysteinyl leukotrienes (LTC4, LTD4, LTE4). When aspirin or NSAIDs further inhibit COX, the already-dominant leukotriene pathway floods the tissue, triggering bronchoconstriction and polyp exacerbation.

In cystic fibrosis, nasal polyps develop through a different mechanism. Defective CFTR channels lead to thick, dehydrated mucus that obstructs sinus drainage, promoting chronic infection and inflammation. A vignette presenting a child or adolescent with bilateral nasal polyps should immediately raise suspicion for cystic fibrosis, as isolated nasal polyposis is uncommon in pediatric populations.

02Classification and Clinical Manifestation

Clinical staging is often described by the degree of obstruction:

03Diagnostic Workup

The workup begins with direct visualization. Anterior rhinoscopy can identify polyps in many cases, but nasal endoscopy is the preferred method because it allows full examination of the middle meatus, sphenoethmoidal recess, and nasopharynx. The polyps appear as pale, glistening, pedunculated masses. A critical distinguishing point: they are insensitive to touch and do not bleed when probed, unlike the vascular mucosa of turbinates (which are often mistaken for polyps by beginners).

CT of the sinuses without contrast is ordered when surgery is being considered, when the diagnosis is uncertain, or when complications are suspected. It provides anatomic detail of the sinuses and ostiomeatal complex. Look for diffuse mucosal thickening and opacification. Unilateral disease, bony destruction, or heterogeneous soft tissue should raise concern for inverted papilloma or sinonasal malignancy, prompting biopsy.

Tissue biopsy is not routinely needed for bilateral, typical-appearing polyps. However, it becomes essential when the polyp is unilateral, friable, or associated with bony erosion. The histologic hallmark of benign inflammatory polyps is eosinophil-predominant infiltration with stromal edema.

Do not forget to order a sweat chloride test for pediatric patients. This is a high-yield test-writer favorite: a child presenting with nasal polyps should trigger cystic fibrosis evaluation.

04Management and Treatment

The first-line treatment for all patients with nasal polyps is intranasal corticosteroids. These are used continuously and indefinitely. They reduce polyp size, improve nasal obstruction, and restore olfaction in many patients. The mechanism is suppression of local eosinophilic inflammation and reduction of mucosal edema.

If the patient has moderate to severe symptoms, add a short course of oral prednisone. This acts as a medical debulking, rapidly shrinking the polyps. The duration should be limited to 5 to 14 days to minimize systemic steroid side effects. After the course, reassess symptom control and polyp burden.

Patients who fail medical therapy after adequate trials (typically 8 to 12 weeks of topical steroids with at least one course of oral steroids) are candidates for endoscopic sinus surgery. The goal of surgery is not curative but rather to remove the polyp burden and restore sinus ventilation so that topical medications can access the sinus mucosa more effectively. Postoperative intranasal steroids are mandatory because recurrence rates are high, particularly in patients with AERD or EGPA.

Dupilumab represents a paradigm shift for patients with recurrent or refractory disease. By blocking IL-4 and IL-13 signaling, it targets the upstream drivers of type 2 inflammation. It reduces polyp size, improves olfaction, and decreases the need for revision surgery and systemic steroids.

For patients with AERD, aspirin desensitization followed by daily aspirin maintenance is recommended after surgery. This modifies the leukotriene-driven pathology and significantly reduces polyp recurrence.

Contraindications and cautions: Long-term oral corticosteroids should be avoided due to cumulative toxicity (osteoporosis, adrenal suppression, hyperglycemia). Leukotriene receptor antagonists (montelukast) may be used as adjunctive therapy in AERD but are not a substitute for intranasal steroids.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on nasal polyp questions is by failing to recognize the critical associations that change management. A vignette describing a child with bilateral nasal polyps is not simply asking you to treat polyps; it is testing whether you will order a sweat chloride test to evaluate for cystic fibrosis. Similarly, a patient with nasal polyps, asthma, and a history of a severe reaction after taking ibuprofen is testing your knowledge of Samter triad and whether you understand that the mechanism is leukotriene overproduction, not an IgE-mediated allergy.

Another common trap involves unilateral polyps. Test-writers use this detail deliberately. Bilateral, pale, nontender polyps point toward benign inflammatory disease. A unilateral mass, especially one that bleeds, should make you consider inverted papilloma, angiofibroma (in an adolescent male), or malignancy. The "next best step" in these cases is imaging before biopsy, particularly for angiofibroma, where blind biopsy can cause catastrophic hemorrhage.

Students also confuse turbinate hypertrophy with polyps. Remember: turbinates are red and shrink with decongestants; polyps are pale and do not respond to decongestants. If the vignette mentions that the intranasal mass "did not change with application of oxymetazoline," the answer is polyps.

Finally, be aware that questions may test the step after failed medical therapy. If a patient has been on intranasal steroids and oral steroid courses without improvement, the next best step is endoscopic sinus surgery, not indefinite systemic steroids. For the most refractory cases (recurrence after surgery), the answer increasingly involves biologic therapy with dupilumab.

The core competency being tested across nasal polyp questions is pattern recognition of key associations (cystic fibrosis in children, AERD in adults, EGPA in systemic disease) and the ability to distinguish benign bilateral polyposis from sinister unilateral pathology.